


The burden of antimicrobial resistance (AMR) in Togo

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **1,000 lives** have been lost each year since 1990 in Togo due to AMR.
- In 2021, there were an estimated **1,320 UI (913-1,730)** deaths attributable to AMR and **6,040 UI (4,320-7,760)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **under 5** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Klebsiella pneumoniae* resistant to fluoroquinolones, *Acinetobacter baumannii* resistant to anti-pseudomonal penicillin / beta-lactamase inhibitors and *Streptococcus pneumoniae* resistant to third-generation cephalosporins.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Togo, a 10% reduction means to decrease the number of deaths associated with AMR to **5,790**, but currently the trend for this country could reach up to **6,840 UI [4,680-9,830]** AMR-associated deaths in 2030.

AMR in Togo

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Togo between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Togo** in 2021, there were an estimated **1,320 UI (913-1,730)** deaths attributable to AMR and **6,040 UI (4,320-7,760)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Togo has the 18th highest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant			Associated			Attributable		
	Mycobacterium tuberculosis 2,020 UI (1,230-2,810)	↑		Klebsiella pneumoniae 1,120 UI (847-1,400)	↑		Klebsiella pneumoniae 259 UI (185-333)	↑	
	Streptococcus pneumoniae 1,380 UI (1,030-1,740)	↓		Streptococcus pneumoniae 1,030 UI (687-1,360)	↓		Acinetobacter baumannii 204 UI (155-253)	↑	
	Klebsiella pneumoniae 1,220 UI (922-1,510)	↑		Escherichia coli 936 UI (638-1,230)	↓		Streptococcus pneumoniae 193 UI (120-266)	↓	
	Escherichia coli 1,010 UI (691-1,330)	↓		Staphylococcus aureus 610 UI (400-820)	↑		Escherichia coli 177 UI (106-247)	↓	
	Staphylococcus aureus 883 UI (671-1,090)	↑		Acinetobacter baumannii 558 UI (404-713)	↑		Pseudomonas aeruginosa 131 UI (86-176)	↑	
	Pseudomonas aeruginosa 835 UI (636-1,030)	↑		Pseudomonas aeruginosa 541 UI (383-700)	↑		Staphylococcus aureus 114 UI (65-164)	↑	
	Non-typhoidal Salmonella 788 UI (367-1,210)	↑		Enterobacter spp. 164 UI (124-203)	↑		Enterobacter spp. 49 UI (36-62)	↑	
	Acinetobacter baumannii 665 UI (501-829)	↑		Serratia spp. 160 UI (114-207)	↑		Serratia spp. 44 UI (31-57)	↑	
	Group B Streptococcus 336 UI (242-430)	↑		Group B Streptococcus 140 UI (90-189)	↑		Mycobacterium tuberculosis 35 UI (0-114)	↑	
	Shigella spp. 287 UI (81-493)	↓		Non-typhoidal Salmonella 129 UI (56-202)	↑		Citrobacter spp. 22 UI (15-28)	↑	

Annualized rate of change (1990-2021)

<-3% -1.5% to 0% 1.5% to 3% >5.0%
-3% to -1.5% 0% to 1.5% 3% to 5%

Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)


Burden Rank	Associated			Attributable		
	Klebsiella pneumoniae TMP-SMX	1,070 UI (804-1,330)	↑	Streptococcus pneumoniae 3GC	77 UI (48-106)	↑
	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib.	1,030 UI (764-1,300)	↑	Klebsiella pneumoniae Fluoroquinolones	59 UI (36-82)	↑
	Escherichia coli Aminopenicillin	930 UI (607-1,250)	↓	Acinetobacter baumannii Anti-pseudomonal	48 UI (37-59)	↑
	Streptococcus pneumoniae TMP-SMX	815 UI (497-1,130)	↓	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib.	47 UI (16-78)	↓
	Klebsiella pneumoniae Fluoroquinolones	811 UI (576-1,050)	↑	Klebsiella pneumoniae TMP-SMX	47 UI (23-70)	↑
	Escherichia coli TMP-SMX	801 UI (547-1,050)	↓	Staphylococcus aureus Methicillin	44 UI (13-76)	↑
	Escherichia coli Beta-Lactam/Lactamase Inhib.	654 UI (440-869)	↓	Pseudomonas aeruginosa Anti-pseudomonal	41 UI (27-55)	↑
	Klebsiella pneumoniae Aminoglycosides	604 UI (420-787)	↑	Pseudomonas aeruginosa Fluoroquinolones	41 UI (25-56)	↑
	Klebsiella pneumoniae 3GC	587 UI (420-755)	↑	Acinetobacter baumannii Fluoroquinolones	40 UI (29-51)	↑
	Acinetobacter baumannii 3GC	533 UI (379-687)	↑	Klebsiella pneumoniae 3GC	40 UI (20-59)	↑

Annualized rate of change (1990-2021)

<-3% -1.5% to 0% 1.5% to 3% >5.0%
-3% to -1.5% 0% to 1.5% 3% to 5%

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) lower respiratory infection (excl. COVID) (5,280 UI (3,960-6,600)), bloodstream infections (4,480 UI (3,320-5,640)), diarrhea (3,050 UI (1,670-4,420)), tuberculosis (2,020 UI (1,230-2,810)) and typhoid fever, paratyphoid fever, and invasive non-typhoidal salmonella (859 UI (440-1,280)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Togo, people aged under 5 saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that under 5 continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the under 5 was 2,200 UI (1,470-2,930), whereas the mortality rate per 100,000 was 932 UI (716-1,150).

Data sources for Togo

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Togo by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	1990-2021	1,032	Study-year datapoints
Microbial or laboratory data without outcome	1990-2021	106	Isolates
Literature studies	1990-2021	2,575	Cases/isolates/susceptibility tests
Antibiotic sales	1990-2021	19	Study-year datapoints

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care's Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>